Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BDKRB1 | P46663 | 10/20 | 0.43 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.40 |
| ▸ | OPRL1 | P41146 | 3/20 | 0.40 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.40 |
| ▸ | HTR2A | P28223 | 1/20 | 0.40 |
| ▸ | HTR2C | P28335 | 1/20 | 0.40 |
| ▸ | HTR7 | P34969 | 1/20 | 0.40 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.39 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.39 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.39 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | SOS1 | Q07889 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5128264 | 0.90 | BDKRB1 (0.45) | BDKRB1 | |
| SCHEMBL5123826 | 0.90 | SOS1 (0.41) | BDKRB1OPRM1OPRL1ADORA2AADORA2B | |
| SCHEMBL5125449 | 0.88 | BDKRB1 (0.42) | BDKRB1OPRM1OPRL1OPRK1HTR2A | |
| SCHEMBL5132598 | 0.87 | BDKRB1 (0.42) | BDKRB1MEN1KMT2A | |
| SCHEMBL3829108 | 0.86 | BDKRB1 (0.44) | BDKRB1 | |
| SCHEMBL5128731 | 0.83 | BDKRB1 (0.43) | BDKRB1 | |
| SCHEMBL5127801 | 0.82 | BDKRB1 (0.44) | BDKRB1 | |
| SCHEMBL5131527 | 0.80 | BDKRB1 (0.60) | BDKRB1 | |
| SCHEMBL5128468 | 0.78 | OPRM1 (0.40) | BDKRB1OPRM1OPRL1OPRK1HTR2A | |
| SCHEMBL5132590 | 0.76 | ALDH1A1 (0.42) | BDKRB1MEN1KMT2ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8580965-B2 | Substituted sulfonamide compounds | GRUENENTHAL GMBH (DE) | 2013-11-12 | — | — | US | claimed |
| US-20080249128-A1 | Substituted Sulfonamide Compounds | GRUENENTHAL GMBH (DE) | 2008-10-09 | — | — | US | claimed |
| US-8580965-B2 | Substituted sulfonamide compounds | GRUENENTHAL GMBH (DE) | 2013-11-12 | — | — | US | disclosed |
| US-20080249128-A1 | Substituted Sulfonamide Compounds | GRUENENTHAL GMBH (DE) | 2008-10-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080249128-A1 | Substituted Sulfonamide Compounds | BDKRB1, BDKRB2, NPSR1 | BDKRB1 1/4885OPRM1 232/4885OPRL1 10/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.